Daniel J. George

16.4k total citations · 4 hit papers
255 papers, 7.9k citations indexed

About

Daniel J. George is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Daniel J. George has authored 255 papers receiving a total of 7.9k indexed citations (citations by other indexed papers that have themselves been cited), including 227 papers in Pulmonary and Respiratory Medicine, 104 papers in Oncology and 72 papers in Cancer Research. Recurrent topics in Daniel J. George's work include Prostate Cancer Treatment and Research (149 papers), Renal cell carcinoma treatment (70 papers) and Radiopharmaceutical Chemistry and Applications (52 papers). Daniel J. George is often cited by papers focused on Prostate Cancer Treatment and Research (149 papers), Renal cell carcinoma treatment (70 papers) and Radiopharmaceutical Chemistry and Applications (52 papers). Daniel J. George collaborates with scholars based in United States, United Kingdom and Canada. Daniel J. George's co-authors include Andrew J. Armstrong, M. Dror Michaelson, Brian I. Rini, Robert J. Motzer, George Wilding, Bruce G. Redman, Sindy T. Kim, Gary R. Hudes, Charles M. Baum and Susan Halabi and has published in prestigious journals such as New England Journal of Medicine, JAMA and Nature Communications.

In The Last Decade

Daniel J. George

241 papers receiving 7.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Activity of SU11248, a Multitargeted Inhibitor of Vascular Endothelial Growth Factor Receptor and Platelet-Derived Growth Factor Receptor, in Patients With Metastatic Renal Cell Carcinoma

2005 1.3k citations Robert J. Motzer, M. Dror Michaelson et al. Journal of Clinical Oncology profile →
Sunitinib in Patients With Metastatic Renal Cell Carcinoma

2006 969 citations Robert J. Motzer, Brian I. Rini et al. profile →
Circulating Tumor Cells from Patients with Advanced Prostate and Breast Cancer Display Both Epithelial and Mesenchymal Markers

2011 536 citations Andrew J. Armstrong, Matthew S. Marengo et al. Molecular Cancer Research profile →
Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer

2020 259 citations Neal D. Shore, Fred Saad et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Daniel J. George United States	37	5.4k	3.4k	3.1k	2.7k	751	255	7.9k
Daniel J. George United States	48	4.7k 0.9×	3.3k 1.0×	2.9k 0.9×	1.9k 0.7×	913 1.2×	255	8.0k
Tomasz Demkow Poland	21	4.3k 0.8×	3.6k 1.1×	2.2k 0.7×	2.3k 0.9×	414 0.6×	77	6.6k
Manuela Schmidinger Austria	33	5.4k 1.0×	3.9k 1.1×	3.0k 1.0×	2.3k 0.8×	517 0.7×	180	8.5k
Eleni Efstathiou United States	41	4.7k 0.9×	2.0k 0.6×	2.4k 0.8×	1.7k 0.6×	1.3k 1.7×	203	7.4k
David Olmos United Kingdom	48	6.3k 1.2×	3.2k 0.9×	4.1k 1.3×	3.2k 1.2×	1.4k 1.9×	233	10.4k
Jorge A. García United States	43	6.2k 1.1×	2.6k 0.7×	2.1k 0.7×	2.4k 0.9×	1.4k 1.9×	213	8.1k
Scott North Canada	39	5.5k 1.0×	2.6k 0.7×	2.8k 0.9×	2.2k 0.8×	1.2k 1.7×	193	7.6k
Michelle S. Ginsberg United States	51	6.0k 1.1×	3.3k 1.0×	3.5k 1.1×	2.1k 0.8×	1.8k 2.4×	193	9.5k
Viktor Grünwald Germany	41	6.8k 1.3×	5.5k 1.6×	4.1k 1.3×	3.0k 1.1×	404 0.5×	328	10.4k
Hidefumi Sasaki Japan	40	7.3k 1.3×	5.0k 1.5×	6.4k 2.1×	2.7k 1.0×	760 1.0×	143	11.9k

Countries citing papers authored by Daniel J. George

Since Specialization

Citations

This map shows the geographic impact of Daniel J. George's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel J. George with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel J. George more than expected).

Fields of papers citing papers by Daniel J. George

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel J. George. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel J. George. The network helps show where Daniel J. George may publish in the future.

Co-authorship network of co-authors of Daniel J. George

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel J. George. A scholar is included among the top collaborators of Daniel J. George based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel J. George. Daniel J. George is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Agarwal, Neeraj, Michael T. Schweizer, Elena Castro, et al.. (2025). MEVROMETOSTAT (PF-06821497) IN COMBINATION WITH ENZALUTAMIDE IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH ABIRATERONE ACETATE: THE PHASE 3, RANDOMIZED MEVPRO-1 STUDY. Urologic Oncology Seminars and Original Investigations. 43(3). 2–3. 1 indexed citations

Choueiri, Toni K., Thomas Powles, David A. Braun, et al.. (2024). 45 INTerpath-004: A phase 2, randomized, double-blind study of pembrolizumab with V940 (mRNA-4157) or placebo in the adjuvant treatment of renal cell carcinoma. The Oncologist. 29(Supplement_1). S15–S15. 3 indexed citations

Kaye, Deborah R., Erik Muser, Laura Morrison, et al.. (2024). Characterizing the real-world economic burden of metastatic castration-sensitive prostate cancer in the United States. Journal of Medical Economics. 27(1). 381–391. 2 indexed citations

Spratt, Daniel E., Daniel J. George, Neal D. Shore, et al.. (2024). Efficacy and Safety of Radiotherapy Plus Relugolix in Men With Localized or Advanced Prostate Cancer. JAMA Oncology. 10(5). 594–594. 4 indexed citations

Kaye, Deborah R., J. Kelly Davis, Sharron L. Docherty, et al.. (2024). Physician Perspectives on the Nonclinical Factors That Contribute to Decision-Making for Advanced Prostate Cancer Care: A Qualitative Study. JU Open Plus. 2(3).

Freedland, Stephen J., Krishnan Ramaswamy, Rickard Sandin, et al.. (2023). Survival and Economic Impact of Rapid Prostate-Specific Antigen Doubling Time in Patients With Nonmetastatic Castration-Resistant Prostate Cancer. Clinical Genitourinary Cancer. 21(4). 419–429. 2 indexed citations

Tutrone, Ronald, Fred Saad, Daniel J. George, et al.. (2023). Testosterone Recovery for Relugolix Versus Leuprolide in Men with Advanced Prostate Cancer: Results from the Phase 3 HERO Study. European Urology Oncology. 7(4). 906–913. 6 indexed citations

Butler, William, Qing Yang, Yiping He, et al.. (2023). Rewiring of the N-Glycome with prostate cancer progression and therapy resistance. npj Precision Oncology. 7(1). 22–22. 14 indexed citations

Kotamarti, Srinath, Anand Shah, John Anderson, et al.. (2022). Initial Longitudinal Outcomes of Risk-Stratified Men in Their Forties Screened for Prostate Cancer Following Implementation of a Baseline Prostate-Specific Antigen. The World Journal of Men s Health. 41(3). 631–631. 1 indexed citations

10.

Brown, Landon C., Susan Halabi, Jason A. Somarelli, et al.. (2022). A phase 2 trial of avelumab in men with aggressive-variant or neuroendocrine prostate cancer. Prostate Cancer and Prostatic Diseases. 25(4). 762–769. 26 indexed citations

11.

Gupta, Santosh, Susan Halabi, Gabor Kemeny, et al.. (2021). Circulating Tumor Cell Genomic Evolution and Hormone Therapy Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer. Molecular Cancer Research. 19(6). 1040–1050. 19 indexed citations

12.

Armstrong, Andrew J., Andrew B. Nixon, Qian Yang, et al.. (2021). Angiokines Associated with Targeted Therapy Outcomes in Patients with Non–Clear Cell Renal Cell Carcinoma. Clinical Cancer Research. 27(12). 3317–3328. 18 indexed citations

13.

George, Daniel J., Jean-François Martini, Michael Staehler, et al.. (2018). Phase III Trial of Adjuvant Sunitinib in Patients with High-Risk Renal Cell Carcinoma: Exploratory Pharmacogenomic Analysis. Clinical Cancer Research. 25(4). 1165–1173. 18 indexed citations

14.

Zhang, Tian, Rengasamy Boominathan, Brad Foulk, et al.. (2016). Development of a Novel c-MET–Based CTC Detection Platform. Molecular Cancer Research. 14(6). 539–547. 36 indexed citations

15.

Sokhandon, Farnoosh, et al.. (2016). Multidetector CT enterography of focal small bowel lesions: a radiological–pathological correlation. Abdominal Radiology. 42(5). 1319–1341. 18 indexed citations

16.

Harrison, Michael R. & Daniel J. George. (2011). Better Late than Early: FDG-PET Imaging in Metastatic Renal Cell Carcinoma. Clinical Cancer Research. 17(18). 5841–5843. 7 indexed citations

17.

Armstrong, Andrew J., Matthew S. Marengo, Sebastian Oltean, et al.. (2011). Circulating Tumor Cells from Patients with Advanced Prostate and Breast Cancer Display Both Epithelial and Mesenchymal Markers. Molecular Cancer Research. 9(8). 997–1007. 536 indexed citations breakdown →

18.

Armstrong, Andrew J., George J. Netto, Michelle A. Rudek, et al.. (2010). A Pharmacodynamic Study of Rapamycin in Men with Intermediate- to High-Risk Localized Prostate Cancer. Clinical Cancer Research. 16(11). 3057–3066. 62 indexed citations

19.

Rini, Brian I., M. Dror Michaelson, Jonathan E. Rosenberg, et al.. (2008). Antitumor Activity and Biomarker Analysis of Sunitinib in Patients With Bevacizumab-Refractory Metastatic Renal Cell Carcinoma. Journal of Clinical Oncology. 26(22). 3743–3748. 321 indexed citations

20.

Motzer, Robert J., M. Dror Michaelson, Bruce G. Redman, et al.. (2005). Activity of SU11248, a Multitargeted Inhibitor of Vascular Endothelial Growth Factor Receptor and Platelet-Derived Growth Factor Receptor, in Patients With Metastatic Renal Cell Carcinoma. Journal of Clinical Oncology. 24(1). 16–24. 1304 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact